189 related articles for article (PubMed ID: 33390181)
1. Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells.
Rizzo A; Satta A; Garrone G; Cavalleri A; Napoli A; Raspagliesi F; Figini M; De Cecco L; Iorio E; Tomassetti A; Mezzanzanica D; Bagnoli M
J Exp Clin Cancer Res; 2021 Jan; 40(1):5. PubMed ID: 33390181
[TBL] [Abstract][Full Text] [Related]
2. Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma.
Granata A; Nicoletti R; Perego P; Iorio E; Krishnamachary B; Benigni F; Ricci A; Podo F; Bhujwalla ZM; Canevari S; Bagnoli M; Mezzanzanica D
Oncotarget; 2015 May; 6(13):11216-30. PubMed ID: 25796169
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis.
Goncharenko-Khaider N; Matte I; Lane D; Rancourt C; Piché A
Mol Cancer; 2012 Nov; 11():84. PubMed ID: 23158473
[TBL] [Abstract][Full Text] [Related]
4. Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.
Granata A; Nicoletti R; Tinaglia V; De Cecco L; Pisanu ME; Ricci A; Podo F; Canevari S; Iorio E; Bagnoli M; Mezzanzanica D
Br J Cancer; 2014 Jan; 110(2):330-40. PubMed ID: 24281000
[TBL] [Abstract][Full Text] [Related]
5. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
[TBL] [Abstract][Full Text] [Related]
6. Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5.
Zhao Y; Tian B; Wang Y; Ding H
Med Sci Monit; 2017 Oct; 23():5096-5105. PubMed ID: 29070784
[TBL] [Abstract][Full Text] [Related]
7. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
[TBL] [Abstract][Full Text] [Related]
8. TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells.
Szliszka E; Mazur B; Zydowicz G; Czuba ZP; Król W
Folia Histochem Cytobiol; 2009; 47(4):579-85. PubMed ID: 20430723
[TBL] [Abstract][Full Text] [Related]
9. Anticancer activity of NOB1-targeted shRNA combination with TRAIL in epithelial ovarian cancer cells.
Lin Y; Xu T; Teng H; Cui M
Int J Clin Exp Pathol; 2015; 8(9):10061-71. PubMed ID: 26617713
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
Saulle E; Petronelli A; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Cognetti F; Humphreys R; Peschle C; Testa U
Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
[TBL] [Abstract][Full Text] [Related]
11. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3.
Abdollahi T; Robertson NM; Abdollahi A; Litwack G
Cancer Res; 2003 Aug; 63(15):4521-6. PubMed ID: 12907626
[TBL] [Abstract][Full Text] [Related]
12. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
[TBL] [Abstract][Full Text] [Related]
13. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
[TBL] [Abstract][Full Text] [Related]
14. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
Horak P; Pils D; Haller G; Pribill I; Roessler M; Tomek S; Horvat R; Zeillinger R; Zielinski C; Krainer M
Mol Cancer Res; 2005 Jun; 3(6):335-43. PubMed ID: 15972852
[TBL] [Abstract][Full Text] [Related]
15. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
[TBL] [Abstract][Full Text] [Related]
16. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
17. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
18. Differential susceptibility of metastatic and primary oral cancer cells to TRAIL-induced apoptosis.
Vigneswaran N; Wu J; Nagaraj N; Adler-Storthz K; Zacharias W
Int J Oncol; 2005 Jan; 26(1):103-12. PubMed ID: 15586230
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial division inhibitor 1 (mdivi-1) enhances death receptor-mediated apoptosis in human ovarian cancer cells.
Wang J; Hansen K; Edwards R; Van Houten B; Qian W
Biochem Biophys Res Commun; 2015 Jan; 456(1):7-12. PubMed ID: 25446129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
